CAP37 and ocular inflammation

CAP37 和眼部炎症

基本信息

项目摘要

DESCRIPTION (provided by applicant): This application is designed to investigate the role of the inflammatory mediator, CAP37, in ocular inflammation. CAP37 was recently identified in the eye in response to bacterial infection. Surprisingly, its localization was not confined to the neutrophil (PMN), where it is known to be constitutively expressed, but it was also found induced in corneal epithelial cells, and vascular endothelial cells of the limbal and ciliary vessels. There are many inflammatory-associated biological activities regulated by CAP37 that confer on this molecule a role in innate host defense against invading pathogens. CAP37 is a potent antibiotic, promotes monocyte chemotaxis, and has immunomodulatory effects on host cells including corneal epithelial cells. The induction of a host defense molecule in the outermost layers of the eye and in the vascular endothelium in response to infection, suggests that it could play a key role in regulating inflammation and healing in the cornea and in the long term form the basis for developing new therapeutics for certain eye infections. It is our hypothesis that CAP37, either released by PMNs or induced in corneal epithelial cells at the site of infection, plays a pivotal role in the inflammatory response of the cornea to infection. We hypothesize that it accomplishes this through a novel, dual mechanism of action based on its antibiotic/anti-inflammatory and immunomodulatory properties. Aim 1: To test the hypothesis that the regulation of proliferation, chemotaxis, and adhesion of corneal epithelial cells in ocular inflammation is dependent on CAP37 and is mediated through the intracellular signaling molecule protein kinase C, we will use techniques that include immunohistochemistry, pharmacological inhibitors, and RNA interference. Aim 2: To test the hypothesis that CAP37 is a biologically relevant mediator in host defense in the eye, we will measure the induction and identity of inflammatory cells, mediators, cytokines, and adhesion molecules in response to the administration of CAP37, its bioactive peptides, and neutralizing antibodies into the corneal stroma. Flow cytometry, ELISA, immunohistochemistry, and RT-PCR will be used to analyze data. Aim 3: To test the hypothesis that the anti-inflammatory and immunomodulatory properties of CAP37 are important for host defense in ocular infection we will use CAP37 and its bioactive peptides in a murine model of Pseudomonas aeruginosa keratitis to determine in vivo efficacy. Relevance to public health: Once corneal integrity is breached, prompt treatment with antibiotics is required to halt the development of infection and harmful sequelae such as ulceration, perforation, scarring, and loss of vision. Unfortunately, the antibiotics currently available for ophthalmic use have serious limitations. We believe our findings will help develop new therapies for treating wounds and infections of the eye based on the biological molecule CAP37 and its bioactive peptides.
描述(由申请人提供):本申请旨在研究炎症介质CAP37在眼部炎症中的作用。CAP37最近在眼睛中被发现是对细菌感染的反应。令人惊讶的是,它的定位并不局限于中性粒细胞(PMN),在那里它被认为是组成性表达的,但它也被发现在角膜上皮细胞、角膜缘血管内皮细胞和睫状血管中被诱导。有许多炎症相关的生物活动由CAP37调节,赋予该分子在先天宿主防御入侵病原体中的作用。CAP37是一种有效的抗生素,促进单核细胞趋化,并对包括角膜上皮细胞在内的宿主细胞具有免疫调节作用。在眼睛最外层和血管内皮中诱导宿主防御分子以应对感染,这表明它可能在调节角膜炎症和愈合中发挥关键作用,并在长期内形成开发某些眼部感染新疗法的基础。我们的假设是,无论是PMNs释放的CAP37,还是在感染部位的角膜上皮细胞中诱导的CAP37,在角膜对感染的炎症反应中起关键作用。我们假设它通过一种基于其抗生素/抗炎和免疫调节特性的新的双重作用机制来实现这一目标。目的1:为了验证眼部炎症中角膜上皮细胞增殖、趋化性和粘附的调节依赖于CAP37并通过细胞内信号分子蛋白激酶C介导的假设,我们将使用包括免疫组织化学、药物抑制剂和RNA干扰在内的技术。目的2:为了验证CAP37是眼部宿主防御的生物学相关介质的假设,我们将测量炎症细胞、介质、细胞因子和粘附分子在给予CAP37、其生物活性肽和中和抗体进入角膜基质后的诱导和识别。流式细胞术,ELISA,免疫组织化学和RT-PCR将用于分析数据。目的3:为了验证CAP37的抗炎和免疫调节特性对眼部感染的宿主防御很重要的假设,我们将在铜绿假单胞菌角膜炎小鼠模型中使用CAP37及其生物活性肽来确定其体内疗效。与公共卫生的相关性:一旦角膜完整性遭到破坏,就需要及时使用抗生素进行治疗,以阻止感染和溃疡、穿孔、疤痕和视力丧失等有害后遗症的发展。不幸的是,目前可用于眼科的抗生素有严重的局限性。我们相信我们的发现将有助于开发基于生物分子CAP37及其生物活性肽的治疗伤口和眼睛感染的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(5)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heloise. ANNE Pereira其他文献

Heloise. ANNE Pereira的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heloise. ANNE Pereira', 18)}}的其他基金

Novel Ophthalmic Product for Corneal Infections and Injuries
用于治疗角膜感染和损伤的新型眼科产品
  • 批准号:
    10156366
  • 财政年份:
    2021
  • 资助金额:
    $ 36.63万
  • 项目类别:
50th Annual Meeting of the Society for Leukocyte Biology (SLB). Leukocyte Memory: Health and Disease
白细胞生物学学会 (SLB) 第 50 届年会。
  • 批准号:
    9398529
  • 财政年份:
    2017
  • 资助金额:
    $ 36.63万
  • 项目类别:
48th Annual Meeting of the Society for Leukocyte Biology - Immunity in Health and Disease
白细胞生物学学会第 48 届年会 - 健康与疾病中的免疫
  • 批准号:
    8986501
  • 财政年份:
    2015
  • 资助金额:
    $ 36.63万
  • 项目类别:
Pilot Projects Program Core
试点项目核心计划
  • 批准号:
    10438749
  • 财政年份:
    2013
  • 资助金额:
    $ 36.63万
  • 项目类别:
Pilot Projects Program Core
试点项目核心计划
  • 批准号:
    10218190
  • 财政年份:
    2013
  • 资助金额:
    $ 36.63万
  • 项目类别:
Development of an antimicrobial peptide therapeutic for Pseudomonas infections
开发治疗假单胞菌感染的抗菌肽
  • 批准号:
    7324392
  • 财政年份:
    2007
  • 资助金额:
    $ 36.63万
  • 项目类别:
Development of an antimicrobial peptide therapeutic for Pseudomonas infections
开发治疗假单胞菌感染的抗菌肽
  • 批准号:
    8142110
  • 财政年份:
    2007
  • 资助金额:
    $ 36.63万
  • 项目类别:
CAP37 and ocular inflammation
CAP37 和眼部炎症
  • 批准号:
    8135325
  • 财政年份:
    2007
  • 资助金额:
    $ 36.63万
  • 项目类别:
CAP37 and ocular inflammation
CAP37 和眼部炎症
  • 批准号:
    7500044
  • 财政年份:
    2007
  • 资助金额:
    $ 36.63万
  • 项目类别:
Development of an antimicrobial peptide therapeutic for Pseudomonas infections
开发治疗假单胞菌感染的抗菌肽
  • 批准号:
    7925577
  • 财政年份:
    2007
  • 资助金额:
    $ 36.63万
  • 项目类别:

相似海外基金

New technologies for targeted delivery of anti-bacterial agents
抗菌药物靶向递送新技术
  • 批准号:
    1654774
  • 财政年份:
    2015
  • 资助金额:
    $ 36.63万
  • 项目类别:
    Studentship
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8416313
  • 财政年份:
    2012
  • 资助金额:
    $ 36.63万
  • 项目类别:
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8298885
  • 财政年份:
    2012
  • 资助金额:
    $ 36.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了